News Release Archives

Note that the releases are accurate at the time of publication but may be subject to change without notice.


Mitsubishi Electric to Deliver Pencil Beam Scanning System for Cancer Therapy at SAGA Heavy Ion Medical Accelerator

Providing more precise particle-beam, contributing for safer cancer treatment

TOKYO, September 12, 2014- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will provide its innovative Pencil Beam Scanning system for cancer treatment at SAGA Heavy Ion Medical Accelerator in Tosu (SAGA HIMAT) in Saga Prefecture, Japan, with operations scheduled to begin in 2017*.

Pencil Beam Scanning is a next generation technology that uses a carbon ion beam with drastically reduced spot size to more accurately and efficiently irradiate complicated tumor volumes. The system enables the delivery of individual layers of pencil beam spots to precise locations, eliminating the need for beam collimation and compensators to adjust the target area. As a result, it provides greater efficiency in time and cost in setting up the treatment fields and improved throughput, as well as increased patient benefit.

SAGA HIMAT is the first heavy-ion therapy facility in the Kyushu area, which started operation in May 2013. More than three hundred patients have been treated at the facility's two treatment rooms and the third room will be installed with the pencil beam scanning system which will be developed in collaboration with National Institute of Radiological Sciences (NIRS) and Heavy Ion Medical Center of Gunma University (GHMC).

Mitsubishi Electric has installed systems at eight out of the twelve particle therapy facilities in Japan, including the only four carbon ion beam systems available in the country. To date, more than 20,000 patients have been treated using the current Broad Beam technology. Mitsubishi Electric will continue to provide and develop advanced particle therapy systems for worldwide use, and is committed to providing superb operational and maintenance supports.

* These products require country specific regulatory approvals prior to first patient use.